Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
3960
Trial Sponsor
Clinical Trial Start Date
July 26, 2021
0Primary Completion Date
September 30, 2024
0Study Completion Date
September 30, 2039
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Intervention Name
Bendamustine0
IL-20
Fludarabine0
FT8190
Cyclophosphamide0
Interventional Trial Phase
Phase 10
Participating Facility
Official Name
A Phase I Study of FT819 in Subjects With B-cell Malignancies0
Last Updated
November 2, 2023
0Allocation Type
Non-Randomized0
Intervention Model
Sequential Assignment0
Masking Type
None (Open Label)0
Study summary
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
